New Melanoma Vaccine Trial Results: What Patients Need to Know

Posted on: October 16th, 2026 by Our Team

A new melanoma treatment is making headlines, and the early news is very exciting.

Researchers have announced positive results from a large Phase 3 trial of a personalized mRNA melanoma vaccine. The treatment is called intismeran autogene, also known as V940 or mRNA-4157. It was developed by Moderna and Merck and is given along with the immunotherapy medicine Keytruda (pembrolizumab).

The new study found that patients who received the personalized treatment plus Keytruda went longer without their melanoma coming back or spreading than patients who received Keytruda alone. The trial included more than 1,100 people with high-risk melanoma that had already been removed with surgery.

For patients, this is an important step forward. But there are also a few things to understand about what the headlines really mean.

Is This a Vaccine That Prevents Melanoma?

No.

When most of us hear the word “vaccine,” we think of a shot that prevents an illness before we get it. This melanoma vaccine works differently.

It is made after a person has already been diagnosed with melanoma.

Doctors send a sample of the patient’s tumor for genetic testing. Scientists look for mutations that make that melanoma different from normal cells. They then make a personalized mRNA treatment designed to teach the patient’s immune system what those melanoma cells look like.

In simple terms, the treatment gives the immune system a “wanted poster” for that person’s cancer cells.

Each treatment can contain instructions targeting up to 34 unique features, called neoantigens, found in that patient’s tumor.

What Did the New Melanoma Vaccine Trial Find?

The newest results come from a Phase 3 study called INTerpath-001.

Patients in the study had stage IIB through stage IV melanoma that had been completely removed with surgery. They received either Keytruda plus the personalized mRNA treatment or Keytruda with a placebo.

On August 19, 2026, researchers announced that the study met two very important goals.

Patients receiving the personalized vaccine plus Keytruda had a significant improvement in the time they remained free of melanoma recurrence. They also had a significant improvement in the time before melanoma spread to distant parts of the body.

The full numbers from this Phase 3 study have not yet been released. Researchers plan to present the detailed results at an upcoming medical meeting.

That means the results are very encouraging, but we still need to see the complete data.

Earlier Results Are Also Encouraging

We already have longer-term information from a smaller Phase 2b trial.

After about five years of follow-up, patients who received the personalized mRNA treatment plus Keytruda had a 49% lower risk of melanoma returning or death compared with patients who received Keytruda alone.

They also had a 59% lower risk of melanoma spreading to a distant part of the body or death. These five-year results were published in the Journal of Clinical Oncology in 2026.

It is important to understand what those percentages mean. They do not mean the vaccine prevents 49% of all melanomas. They describe the difference in risk between the two groups of patients in the study.

Why Is This Such a Big Deal?

Melanoma is one of the most serious forms of skin cancer.

When melanoma is found early, surgery can often cure it. But some deeper or more advanced melanomas have a higher risk of coming back, even after they have been completely removed.

Modern immunotherapy has already greatly improved melanoma treatment. A personalized cancer vaccine could give doctors another way to help the immune system find and destroy melanoma cells that may remain in the body after surgery.

“What makes these results so exciting is that treatment is becoming increasingly personal,” says Thomas Knackstedt, MD, board-certified dermatologist at Peak Skin Center. “Instead of treating every melanoma exactly the same way, we are learning how to use information from an individual patient’s tumor to help the immune system recognize that specific cancer.”

Can I Get the Melanoma Vaccine Now?

Not as a routine treatment yet.

Intismeran autogene is still an investigational treatment. The companies developing it plan to discuss the Phase 3 results with regulators, including the FDA.

If it is eventually approved, it would most likely be used for certain patients with higher-risk melanoma after surgery, rather than for every person who develops melanoma.

Patients with melanoma should discuss treatment decisions with their dermatologist, surgical team, and melanoma oncology team.

Does This Change the Importance of Finding Melanoma Early?

No. In fact, early detection remains one of the most important tools we have.

Even the new vaccine study started with patients who had already undergone surgery to remove their melanoma.

Finding melanoma when it is small and still limited to the skin can make treatment much simpler and can greatly improve the chance of a good outcome.

Watch for the ABCDE warning signs of melanoma:

• A — Asymmetry: One half of a mole does not look like the other.
• B — Border: The edges are uneven, blurred, or irregular.
• C — Color: A spot has several colors or an unusual color.
• D — Diameter: The spot is getting larger, although melanomas can also be small.
• E — Evolving: A mole or spot is changing in size, shape, color, or symptoms.

Any spot that is new, changing, bleeding, itching, or simply looks different from your other moles deserves attention.

Melanoma Screening in Fuquay-Varina, NC

The new melanoma vaccine research is an exciting look at where skin cancer treatment may be headed. But the best opportunity to treat melanoma is still to find it as early as possible.

At Peak Skin Center in Fuquay-Varina, North Carolina, our dermatology team provides comprehensive skin cancer examinations, evaluation of changing or concerning moles, skin biopsies, and treatment of skin cancer.

Thomas Knackstedt, MD, is a board-certified dermatologist and fellowship-trained Mohs surgeon with extensive experience diagnosing and treating skin cancer.

If you have a changing mole, a new spot that concerns you, or are due for a skin cancer screening, schedule an appointment with Peak Skin Center.

Early detection matters. And as these new melanoma vaccine results show, the future of melanoma treatment is becoming more personalized than ever.